Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Digoxin Pharmacokinetic Interaction Study
NCT04322552Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax) of Digoxin and Area Under the Curve (AUC) of Digoxin. Started Mar 2020; status: completed.
02
Drugs
Rivoceranib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04322552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322552.